MX2019002962A - Inhibidores espirobiciclicos de la interaccion de menina-mll. - Google Patents

Inhibidores espirobiciclicos de la interaccion de menina-mll.

Info

Publication number
MX2019002962A
MX2019002962A MX2019002962A MX2019002962A MX2019002962A MX 2019002962 A MX2019002962 A MX 2019002962A MX 2019002962 A MX2019002962 A MX 2019002962A MX 2019002962 A MX2019002962 A MX 2019002962A MX 2019002962 A MX2019002962 A MX 2019002962A
Authority
MX
Mexico
Prior art keywords
menin
spiro bicyclic
mll interaction
bicyclic inhibitors
mll
Prior art date
Application number
MX2019002962A
Other languages
English (en)
Inventor
René Angibaud Patrick
Noëlle Constance Pilatte Isabelle
Alexis Georges Querolle Oliver
Pande Vineet
Herkert Barbara
Jason Krosky Daniel
Nathaniel Patrick Aaron
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Priority claimed from PCT/EP2017/073004 external-priority patent/WO2018050686A1/en
Publication of MX2019002962A publication Critical patent/MX2019002962A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invencion se refiere a agentes farmaceuticos utiles para la terapia y/o profilaxis en un mamifero, y en particular a compuestos espirociclicobiciclicos, a una composicion farmaceutica que comprende dichos compuestos, y a su uso como inhibidores de la interaccion entre proteínas menina/MLL, utiles para tratar enfermedades tales como cancer, sindrome mielodisplasico (MDS) y diabetes.
MX2019002962A 2016-09-14 2017-09-13 Inhibidores espirobiciclicos de la interaccion de menina-mll. MX2019002962A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662394295P 2016-09-14 2016-09-14
EP16192431 2016-10-05
PCT/EP2017/073004 WO2018050686A1 (en) 2016-09-14 2017-09-13 Spiro bicyclic inhibitors of menin-mll interaction

Publications (1)

Publication Number Publication Date
MX2019002962A true MX2019002962A (es) 2019-07-04

Family

ID=59895299

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002962A MX2019002962A (es) 2016-09-14 2017-09-13 Inhibidores espirobiciclicos de la interaccion de menina-mll.

Country Status (15)

Country Link
US (1) US11220517B2 (es)
EP (1) EP3512857B1 (es)
JP (1) JP6975791B2 (es)
KR (1) KR102493644B1 (es)
CN (1) CN109689663B (es)
AU (1) AU2017326487B2 (es)
BR (1) BR112019004691A2 (es)
DK (1) DK3512857T3 (es)
ES (1) ES2872003T3 (es)
HR (1) HRP20210514T1 (es)
HU (1) HUE053907T2 (es)
IL (1) IL265233B (es)
LT (1) LT3512857T (es)
MX (1) MX2019002962A (es)
SI (1) SI3512857T1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019004691A2 (pt) 2016-09-14 2019-06-25 Janssen Pharmaceutica Nv inibidores bicíclicos em espiro da interação menina-mll
MA46228A (fr) * 2016-09-14 2019-07-24 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
ES2901227T3 (es) 2016-12-15 2022-03-21 Janssen Pharmaceutica Nv Inhibidores de azepano de la interacción menina-MLL
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
CN112812584A (zh) * 2019-11-16 2021-05-18 复旦大学 一种含氮杂环丁烷螺环结构的荧光染料及其制备方法和应用
TW202138367A (zh) * 2019-12-19 2021-10-16 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
CN114478568A (zh) * 2020-10-27 2022-05-13 苏州优理生物医药科技有限公司 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用
CN114516873A (zh) * 2020-11-18 2022-05-20 苏州优理生物医药科技有限公司 一种螺环类化合物、包含其药物组合物及其应用
CN116903609A (zh) * 2021-11-05 2023-10-20 上海优理惠生医药有限公司 一种化合物、包含其的药物组合物及其应用
WO2023244870A1 (en) * 2022-06-17 2023-12-21 INSTITUTE FOR CANCER RESEARCH d.b.a THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER Compositions and methods for control of transient site-specific copy gains, genomic insertions, and rearrangements associated with mixed lineage leukemia

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
EP1476455A1 (en) 2002-02-19 2004-11-17 Cv Therapeutics, Inc. PARTIAL AND FULL AGONISTS OF A sb 1 /sb ADENOSINE RECEPTORS
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
JP4660199B2 (ja) 2002-12-23 2011-03-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換１−ピペリジン−４−イル−４−アゼチジン−３−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
MXPA06013250A (es) 2004-05-14 2007-02-28 Abbott Lab Inhibidores de quinasa como agentes terapeuticos.
US20080102068A1 (en) 2005-01-19 2008-05-01 Coleman Paul J Mitotic Kinesin Inhibitors
GB0713602D0 (en) 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
JP5343975B2 (ja) 2008-10-06 2013-11-13 日本電気株式会社 無線通信装置、無線通信システム、無線通信装置の制御方法、及びプログラム
JP2011026305A (ja) 2009-06-24 2011-02-10 Daiichi Sankyo Co Ltd イミダゾールカルボニル化合物を含有する医薬組成物
WO2011020567A1 (de) * 2009-08-20 2011-02-24 Bayer Cropscience Ag 3-triazolylphenyl-substituierte sulfid-derivate als akarizide und insektizide
US8993552B2 (en) 2009-09-04 2015-03-31 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
EP2590981B1 (en) * 2010-07-09 2014-09-03 Leo Pharma A/S Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
CN103339139A (zh) 2010-12-03 2013-10-02 Epizyme股份有限公司 组蛋白甲基转移酶的7-氮杂嘌呤调节剂及其使用方法
EP2646455A4 (en) 2010-12-03 2014-04-02 Epizyme Inc MODULATORS OF HISTON METHYLTRANSFERASE AND METHOD OF USE THEREOF
EP2620094B1 (en) 2011-08-01 2015-10-14 Olympus Corporation Apparatus for displaying shape of insertion portion
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
CN103664991B (zh) 2012-09-19 2016-12-28 中国科学院福建物质结构研究所 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途
US9730940B2 (en) * 2012-11-16 2017-08-15 Merck Sharp & Dohme Purine inhibitors of human phosphatidylinositol 3-kinase delta
KR102173874B1 (ko) 2012-12-21 2020-11-05 에피자임, 인코포레이티드 테트라하이드로- 및 디하이드로-이소퀴놀린 prmt5 억제제 및 이의 용도
EP2935240A1 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP2016505002A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用
AU2014249233A1 (en) * 2013-03-13 2015-09-24 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2015171738A2 (en) * 2014-05-06 2015-11-12 The Procter & Gamble Company Fragrance compositions
US20170119769A1 (en) 2014-06-10 2017-05-04 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016081732A1 (en) 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
JP6584521B2 (ja) 2015-02-24 2019-10-02 ファイザー・インク 抗がん剤として有用な置換ヌクレオシド誘導体
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
US10588907B2 (en) 2015-06-04 2020-03-17 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
US20190010167A1 (en) * 2015-12-22 2019-01-10 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
KR102419524B1 (ko) 2016-03-16 2022-07-08 쿠라 온콜로지, 인크. 메닌-mll의 가교된 이환식 억제제 및 사용 방법
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
EP3452461B1 (en) 2016-05-02 2021-09-08 The Regents of The University of Michigan Piperidines as menin inhibitors
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
BR122024002146A2 (pt) 2016-06-10 2024-03-05 Vitae Pharmaceuticals, Inc. Compostos inibidores da interação de menina-llm e forma cristalina destes
WO2018024602A1 (en) * 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
JP7071644B2 (ja) 2016-09-06 2022-05-19 株式会社スリーボンド 熱硬化型導電性接着剤
MA46228A (fr) 2016-09-14 2019-07-24 Janssen Pharmaceutica Nv Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
CA3033239A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
BR112019004691A2 (pt) 2016-09-14 2019-06-25 Janssen Pharmaceutica Nv inibidores bicíclicos em espiro da interação menina-mll
BR112019005030A2 (pt) 2016-09-16 2019-06-18 Vitae Pharmaceuticals Inc inibidores da interação de menina-llm
EA201991448A1 (ru) 2017-01-06 2019-12-30 Янссен Фармацевтика Нв Азепановые ингибиторы взаимодействия менин-mll
JP2020514388A (ja) 2017-03-24 2020-05-21 クラ オンコロジー，インク． 血液悪性腫瘍およびユーイング肉腫を処置するための方法

Also Published As

Publication number Publication date
JP6975791B2 (ja) 2021-12-01
DK3512857T3 (da) 2021-05-10
ES2872003T3 (es) 2021-11-02
HRP20210514T1 (hr) 2021-05-14
KR20190045242A (ko) 2019-05-02
BR112019004691A2 (pt) 2019-06-25
JP2019532100A (ja) 2019-11-07
EP3512857A1 (en) 2019-07-24
IL265233A (en) 2019-05-30
HUE053907T2 (hu) 2021-07-28
AU2017326487B2 (en) 2021-08-05
CN109689663A (zh) 2019-04-26
SI3512857T1 (sl) 2021-07-30
CN109689663B (zh) 2023-04-14
AU2017326487A1 (en) 2019-02-28
US11220517B2 (en) 2022-01-11
LT3512857T (lt) 2021-04-12
KR102493644B1 (ko) 2023-01-30
US20190211036A1 (en) 2019-07-11
EP3512857B1 (en) 2021-02-24
IL265233B (en) 2021-06-30

Similar Documents

Publication Publication Date Title
MX2019002959A (es) Inhibidores biciclicos condensados de la interaccion de menina-mll.
MX2019002962A (es) Inhibidores espirobiciclicos de la interaccion de menina-mll.
MX2022013841A (es) Inhibidores de la interaccion de menina-mll.
EA201990699A1 (ru) Спиробициклические ингибиторы взаимодействия менин–mll
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MX2018007703A (es) Inhibidores de la interaccion de menina-linaje leucemico mixto.
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
PH12019502810A1 (en) Bicyclic heterocycles as fgfr inhibitors
CL2017003073A1 (es) Inhibidores de tirosina-cinasas
EP3603661A3 (en) Rna containing composition for treatment of tumor diseases
NZ719905A (en) Bicyclic heterocycle compounds and their uses in therapy
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
EA201690159A1 (ru) Способы и композиции для лечения рака
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
PH12017501122A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
EA202191301A1 (ru) СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
MX2017009608A (es) Compuestos anticancerigenos.
MX2023013176A (es) Derivados espiro sustituidos.
MX2023013174A (es) Derivados espiro sustituidos.
MX2019007067A (es) Inhibidores de azepano de la interacción menina-mll.
EA201990700A1 (ru) Конденсированные бициклические ингибиторы взаимодействия менин–mll
ECSP18000097A (es) Inhibidores de tirosina-cinasas